IP21-002, New Vaccine Surveillance Network
IP21-002, New Vaccine Surveillance Network
批准号:
10674583
负责人:
Marian G Michaels
金额:
$275.0万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2026-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY (For Components A, B, and C). Acute gastroenteritis (AGE) and acute respiratory illness (ARI)
are leading causes of childhood disease, accounting for a large proportion of hospitalizations, Emergency
Department (ED) visits, and outpatient visits annually in the US. These illnesses are caused by diverse
pathogens, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza viruses,
rhinovirus, enterovirus (EV), coronavirus including SARS-CoV-2, adenovirus, rotavirus, norovirus, astrovirus,
and sapovirus. Moreover, some of these viruses are associated with other emerging childhood syndromes,
including acute flaccid myelitis (AFM) associated with EV, and multisystem inflammatory syndrome in children
(MIS-C) associated with SARS-CoV-2. Thus, viral AGE and ARI are of major public health importance, and
result in serious long-term consequences for some children. There are few or no effective antivirals for these
viruses and vaccination is the most promising intervention. Our goals are to conduct active, prospective
population-based surveillance for AGE and ARI; to define the burden of vaccine-preventable diseases;
describe the clinical features, natural history, and population dynamics; and establish vaccine effectiveness
(VE) of licensed and impending vaccines and monitor VE over time. The New Vaccine Surveillance Network
(NVSN) will facilitate these goals. We propose four Specific Aims:
Aim 1: to conduct prospective active surveillance for AGE due to norovirus, rotavirus, and other
enteric viruses among children seeking healthcare in ED, inpatient, and outpatient settings.
(Component A, Mandatory Component 1; Optional Component B)
Aim 2: to conduct prospective active surveillance for ARI due to respiratory viruses in these settings.
(Component A, Mandatory Component 1; Optional Component B)
Aim 3: to conduct prospective active surveillance for AFM syndrome in these settings. (Component A,
Mandatory Component 2)
Aim 4: to conduct prospective active surveillance for MIS-C. (Optional Component C)
The Pittsburgh site has extensive experience with pediatric clinical research, including as a top enrolling NVSN
site in the current NVSN cycle. UPMC Children’s Hospital of Pittsburgh (CHP) has a catchment area of >5.5
million people and admits >95% of hospitalized children in the surrounding county of >1.2 million. Thus, the
environment is excellent for population-based research. The experienced investigative team includes experts
from pediatric infectious diseases, critical care, rheumatology, and cardiology. The data and samples collected
in this project will facilitate the capacity to calculate VE for multiple licensed and pending vaccines. The results
of this project will inform best practices for diagnosis and treatment, guide vaccine recommendations, and
determine public health interventions to prevent viral illness-related medical visits among children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IP21-002, New Vaccine Surveillance Network
-
批准号:10347837
-
项目类别:
-
资助金额:$140.21万
-
财政年份:2021
-
负责人:Marian G Michaels
-
依托单位:
IP21-002, New Vaccine Surveillance Network
-
批准号:10472400
-
项目类别:
-
资助金额:$192.42万
-
财政年份:2021
-
负责人:Marian G Michaels
-
依托单位:
New Vaccine Surveillance Network
-
批准号:9206271
-
项目类别:
-
资助金额:$21.43万
-
财政年份:2016
-
负责人:Marian G Michaels
-
依托单位:
New Vaccine Surveillance Network
-
批准号:9333104
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2016
-
负责人:Marian G Michaels
-
依托单位:
New Vaccine Surveillance Network SUPPLEMENT
-
批准号:9763386
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2016
-
负责人:Marian G Michaels
-
依托单位:
New Vaccine Surveillance Network
-
批准号:10179273
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2016
-
负责人:Marian G Michaels
-
依托单位:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
-
批准号:2472249
-
项目类别:
-
资助金额:$7.81万
-
财政年份:1997
-
负责人:Marian G Michaels
-
依托单位:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
-
批准号:6169114
-
项目类别:
-
资助金额:$11.93万
-
财政年份:1997
-
负责人:Marian G Michaels
-
依托单位:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
-
批准号:2886043
-
项目类别:
-
资助金额:$8.98万
-
财政年份:1997
-
负责人:Marian G Michaels
-
依托单位:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
-
批准号:2671441
-
项目类别:
-
资助金额:$7.85万
-
财政年份:1997
-
负责人:Marian G Michaels
-
依托单位:
BABOON CMV--DISEASE RISK AFTER XENOTRANSPLANTATION
-
批准号:6372573
-
项目类别:
-
资助金额:$11.93万
-
财政年份:1997
-
负责人:Marian G Michaels
-
依托单位:
国内基金
海外基金
登录
查看更多内容
锌粉(002)晶面定向调控及其负极性能强化机理研究
-
批准号:2025JJ70625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:曹鹏辉
-
依托单位:
新型核素偶联药载体JBN002-DOTA的开发及其在肿瘤诊疗中的应用
-
批准号:82373174
-
项目类别:面上项目
-
资助金额:60万元
-
批准年份:2023
-
负责人:杨杰
-
依托单位:
tiRNA-Val-CAC-002介导ITGB3/PI3K/Akt调控FB自噬促进OSF发生机制研究
-
批准号:2023JJ30946
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:吴颖芳
-
依托单位:
双胍新衍生物SMK-002阻断PKM2入核下调脂质合成抑制EMT阻止膀胱癌转移的作用和机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:杨小平
-
依托单位:
tiRNA-Gly-GCC-002 调控FKBP5 在狼疮性肾炎肾小管上皮细胞损伤中的作用及机制研究
-
批准号:LY22H050004
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:陈朝生
-
依托单位:
关键挥发性有机物介导根际促生菌NRCB002定殖的根际生物学机制
-
批准号:32172673
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:高南
-
依托单位:
(002)取向石墨化碳材料的制备及其储钾性能
-
批准号:22075268
-
项目类别:面上项目
-
资助金额:63.0万元
-
批准年份:2020
-
负责人:林宁
-
依托单位:
外泌体lncRNAuc002ktr.3在肺鳞癌顺铂耐药中的作用及其作为新型耐药标志物的临床价值
-
批准号:81972006
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:王保龙
-
依托单位:
宿主LncRNAs LNC_002与Linc00152调控肠道病原菌感染炎症反应的分子机制研究
-
批准号:81902027
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2019
-
负责人:王建伟
-
依托单位:
RELA/ LncRNA-uc002jit.1/PARP1形成环路调节DNA修复对DNA损伤药物清除白血病干细胞的影响
-
批准号:81872898
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:吴丽贤
-
依托单位: